INOVIO to Present at Upcoming Scientific Conferences
Get Alerts INO Hot Sheet
Join SI Premium – FREE
National HPV Conference (
- Oral presentation: DNA Immunotherapy (INO-3107) Results in a 72% Overall Response Rate in Year 1 for Treatment of Recurrent Respiratory Papillomatosis Caused by HPV-6 & 11
- Panel: Recurrent Respiratory Papillomatosis: Lessons Learned, Clinical Advances and Patient Experiences – Moderated by
Kim McClellan , RRP Foundation President
World Vaccine Congress (
- Oral presentation: A New Frontier in mAb Therapeutics: DNA-Encoded Monoclonal Antibodies (DMAb™) as Next Gen DNA Medicine
- Oral presentation: DNA Immunotherapeutics in the Treatment of Cancers and Virally-Mediated Diseases
Festival of Biologics (
- Oral presentation: Advancing DNA Medicine: INO-3107 for Recurrent Respiratory Papillomatosis
Available abstracts will be shared on INOVIO's website following presentations.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media:
Investors:
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302424147.html
SOURCE INOVIO Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Technological Breakthrough丨Niutech's Titanium-Iron Tailings Reduction and Enrichment Technology and Equipment Boost Global Strategic Mineral Resource Recovery
- ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406
- Vanessa Hudgens’ Picks Are Flying Off Shelves, EKOUAER Loungewear That Understands Every Side of Life
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share